Pre-Seed28 September 2021

Sanome secures £2m pre-seed funding from Heal Capital and others for home diagnostics

The funding round was led by Heal Capital and will support team expansion and product development.

£2.0MPre-Seed

Sanome builds a diagnostics innovation engine that combines multiple biomarkers to create medical grade home testing products. The firm focuses on early detection and prevention of diseases.

Sanome has secured £2m in its first institutional funding round to advance its home testing diagnostics platform. The investment was led by Heal Capital, with additional backing from Crista Galli Ventures, Selvedge Ventures, o2h Ventures, Meltwind, and angels including David Cleevely and Pam Garside. The company plans to allocate the capital towards expanding its team across London, Amsterdam, and Cambridge, alongside securing key commercial partnerships to validate its initial diagnostic candidates.

The health start-up combines software, artificial intelligence, and biomarker development to create medical grade diagnostic products intended to improve patient outcomes and lower healthcare costs. Its approach seeks to bring diagnostics closer to patients and enable early disease detection. Founders Benedikt von Thüngen and Marc van der Schee bring prior scaling experience from ventures such as Owlstone Medical and Speechmatics.

From the founder

"Healthcare touches each and every one of us and the recent pandemic has highlighted that at a global level. It showed the need to bring healthcare closer to people’s homes and that we need to leverage many of the recent innovations in digital health and consumer biotech to capture as many data points about human health as possible. This will transform our understanding of the human body and our approach to disease detection and management. At Sanome we are working toward developing multiple at home health tools to drive disruption within the healthcare landscape to benefit each one of us"

Benedikt von Thüngen

CEO at Sanome

Investor perspective

"Sanome will change the way patients, providers and payers interact with healthcare. By pioneering a new model for IVD innovation, they can create medical-grade diagnostics that truly focus on solving our healthcare system’s most pressing problems. We could not be happier to be supporting Sanome’s exceptional founding team on the journey to make healthcare inclusive, preventative and proactive."